{"preliminary_commentary":{"by_channel":{"x_thread":5,"youtube":3,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04797780\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"SELECT MDS-1","nct_id":"NCT04797780","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=select-mds-1-nct04797780. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Tamibarotene: 6 mg administered orally twice per day (BID) on Days 8 through 28 of each 28-day treatment cycle.\n\nAzacitidine: 75 mg/m\\^2 administered intravenously or subcutaneously each day on Days 1 through 7 of each 28-day treatment cycle.","label":"Tamibarotene + Azacitidine","type":"EXPERIMENTAL"},{"description":"Placebo: Tamibarotene-matching tablets administered orally BID on Days 8 through 28 of each 28-day treatment cycle.\n\nAzacitidine: 75 mg/m\\^2 administered intravenously or subcutaneously each day on Days 1 through 7 of each 28-day treatment cycle.","label":"Tamibarotene Matched Placebo + Azacitidine","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-11-13","type":"ACTUAL"},"conditions":["Myelodysplastic Syndromes"],"enrollment":{"count":246,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Tamibarotene","otherNames":["SY-1425"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"},{"name":"Azacitidine","otherNames":[],"type":"DRUG"}],"last_update":"2025-04-10","lead_sponsor":"Syros Pharmaceuticals","official_title":"A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-11-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With Complete Remission (CR)","timeFrame":"Up to 45 months"}],"references":[{"citation":"DeZern AE, Thepot S, de Botton S, Patriarca A, Deeren D, Torregrossa-Diaz JM, Marconi G, Bernal T, Bergua Burgues J, Xicoy B, Jonasova A, Zeidan AM, Dimicoli-Salazar S, Simand C, Valcarcel D, Diez Campelo M, Chai-Ho W, Saini L, Garnier A, Geissler K, Ofran Y, Nagy Z, Krishnamurthy P, Lubbert M, Basak G, Carraway HE, Sallman DA, Borate U, Santini V, Campbell V, Fenaux P, Braun T, Lanza F, Zaucha JM, Roth DA, Paul S, Roy P, Kelly MJ, Volkert A, Chisholm J, Malak TA, Klimek VM, Cluzeau T. Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS. Blood Adv. 2025 Aug 26;9(16):4090-4099. doi: 10.1182/bloodadvances.2025016229.","pmid":"40334070","type":"DERIVED"},{"citation":"Stahl M, DeZern AE. Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? Lancet Haematol. 2024 Jan;11(1):e5-e7. doi: 10.1016/S2352-3026(23)00343-5. Epub 2023 Dec 5. No abstract available.","pmid":"38065202","type":"DERIVED"}],"start_date":{"date":"2021-02-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome","url":"https://clinicaltrials.gov/study/NCT04797780"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/select-mds-1-nct04797780"}